Bennet Cecil, M.D
May 1973: BA with honors
Major in Chemistry University of Louisville
May 1977: M.D. University of Louisville School of Medicine
July 1977 to June 1979: Resident in Pathology
Duke University Medical Center
July 1979-Jan 1981: Resident in Internal Medicine
Moses Cone Memorial Hospital
Greensboro, North Carolina
Affiliated with the University of North Carolina
July 1987-June 1989: Fellow (Gastroenterology/Hepatology)
University of Louisville Affiliated Hospitals
Louisville, KY 40292
Chief: Richard Redinger, M.D.
March 1982-May 1987: Internal Medicine Solo Practice
July 1989-May 1996: Private Practice
September 1996-May 1997: Staff Physician,
Primary Care Blue Clinic
Ireland Army Hospital
Fort Knox, Kentucky
May 1997-May 1998:Assistant Professor of Medicine
University of Louisville School of Medicine
May 1998- Present: Assistant Clinical Professor of Medicine
University of Louisville School of Medicine
Corporate Medical Director
Hepatitis C Treatment Centers Inc.
Diplomate American Board Internal Medicine 1982
Diplomate American Board Gastroenterology 1989
Honors and Awards
Alpha Omega Alpha Medical Honor Society 1977
Dr. Morris Newberg Scholarship Award (First in medical school class in Internal Medicine)
Web Site: www.hepatitisdoctor.com
Cecil B, Woodard B, Mickey DD, et al: Renal Carcinosarcoma. Ultrastructure and transplantation into athymic mice. Arch Pathol Lab Med 1980; May 104(5): 276-9.
Cecil B, Larson G, Sewell C, Redinger RR: Abdominal pain from intestinal Duplication. J Clin Gastroenterology 1990; Feb. 316-319.
Lee J David, Cecil Bennet D, Brown Paul E, Wright Richard A: A Cohen Test does not predict outcome in achalasia after pneumatic dilation. Gastrointestinal Endoscopy 1992; Aug 39(2): 157-60.
Results of methylene- blue directed biopsy is similar to conventional biopsy for the diagnosis of intestinal metaplasia and dysplasia in Barrett’s esophagus Mukunda B Ray,
Stephanie Mayfield-Stokes, Bennet Cecil, Bahram Forouzandeh, April Davis, Mark Wilson, John M Wo: abstract presented at ASGE Topic Forum DDW Orlando FLA May 18, 1999
Bennet D. Cecil Individualized treatment of hepatitis C patients with Rebetron AASLD Abstract 1844 Hepatology, Vol 30, No. 4, Pr 2, 1999 621A
Bennet D. Cecil, Phyllis Slone, Stephanie Mayfield-Stokes, Carlo Tamburro Hepatitis C antibodies do not predict cirrhosis or severe fibrosis in alcoholics AASLD Abstract 1843 Hepatology, Vol 30, No. 4, Pt 2, 1999 621
Anthony Martin, P Wilfredo Canchis, Carlo Tamburro, Philp Fortwengler,Bennet Cecil, Allen Cox, Edward Adler et al. Combination therapy with low dose interferon and ribavirin in naïve patients with hepatitis C. AASLD Abstract 1839. Hepatology, Vol 30, No 4 Pt 2.
Bennet D. Cecil, Mary Lavelle. Elevated weight is a common reason for Rebetron failure in veterans: Failure can be changed to success by increasing the interferon dose. AASLD Poster Presentation #260 Gastroenterology 118 No 4 Suppl 2 part 1 of 2
Bennet D. Cecil, Tami Hill, Mary Lavelle. Hepatitis C patients should be given individualized combination therapy (interferon plus ribavirin) to reach an undetectable HCV-RNA and then treated and additional 20 weeks. AASLD abstract Gastroenterology 118 No 4 Suppl 2 part 2 of 2
Bennet D. Cecil, Tami Hill. Individualized therapy with Infergen and compounded ribavirin is an effective and economical treatment for hepatitis C. AASLD abstract 6486 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
Bennet D. Cecil, Mary Lavelle, Marylee Rothschild, John Burke A systematic organized team approach with individualized care of each hepatitis C patient allows successful treatment of US veterans with hepatitis C. AASLD abstract 6487 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
Bennet D. Cecil, Mary Lavelle. Causes of death in 93 US veterans with hepatitis C. AASLD abstract 6488 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
Bennet D. Cecil, Mary Lavelle, Marylee Rothschild, John Burke. Rebetron at standard doses is not effective in US veterans with hepatitis C. Failure is converted to success with individualized therapy. Abstract 6489 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
Bennet D. Cecil, Tami Hill Mary Lavelle. Plotting the log of HCV-RNA versus time is a useful method to monitor treatment of hepatitis C patients and to guide dose modifications. AASLD abstract 6490 Gastroenterology 118 No 4 Suppl part 2 of 2
Bennet D. Cecil, Mary Lavelle. Recent Advances in Hepatitis C J Ky Med Assoc 2000 Oct;98(10):440-4
Bennet Cecil, Tami Hill, Mary Lavelle Decompensated hepatitis C cirrhotic patients can be safely treated with titrated doses of interferon and ribavirin; they have a highly significant HCV-RNA response to treatment. Supplement to Hepatology, 30, No. 4 Pt 2 2000 AASLD abstract1570
Bennet Cecil. Individualized Antiviral therapy Using Viral Kinetics for Hepatitis C Patients. Louisville Medicine 2001 July;49 (2):83-84
Co investigator VA Cooperative Study 391. Effect of Polyunsaturated Lecithin on Liver Fibrosis.
Co investigator VA Cooperative Study 352. Colchicine in the Treatment of Alcoholic Cirrhosis of the Liver.
Co investigator Protocol R97-024. Intron A + Ribavirin for Treatment of Patients with Chronic Hepatitis C not Previously Treated with Interferon.
Co investigator Protocol R96-419. Intron A + Ribavirin for Treatment of Patients with Interferon –Refractory or Interferon-Relapsed Chronic Hepatitis C.
Two protocols using Infergen monotherapy
Two protocols using Pegasys plus ribavirin
One protocol using PegIntron plus ribavirin
American Gastroenterological Association
Jefferson County Medical Society
Kentucky Medical Association